Drug companies could face a tougher pricing system in Canada if proposals currently out for consultation are implemented. Health Canada is seeking feedback on measures that would force companies to disclose their confidential pricing arrangements with public drug plans and others that would see the Patented Medicines Review Board (PMPRB) using QALYs to decide if drugs are over-priced.
Canada Plans To Force Firms To Disclose Confidential Pricing Deals
Companies operating in Canada could face pharmacoeconomic evaluations to decide if drugs are over-priced as well as a requirement to disclose information that could impair the confidentiality of pricing agreements.
